Fundraising Fox

Vaxess Technologies, Inc.

Cambridge, US · Founded 2012 · Delaware corporation · 2 known investors

Biotech

Founders & leadership

LV
Livio ValentiExecutive Officer
KK
Kathryn KosudaExecutive Officer, Director
MD
Matthew DirckxExecutive Officer
LT
Lynda TusseyExecutive Officer
JS
John SpiridigliozziExecutive Officer
WT
Weiner TilsnerExecutive Officer
JK
Jonathan KlugeExecutive Officer
RS
Rachel ShaExecutive Officer, Director
FO
Fiorenzo OmenettoDirector
JC
James ConnollyDirector
MS
Michael SchraderExecutive Officer, Director
SH
Shuenn HoExecutive Officer

Investors · 2

Mission BiocapitalreportedSan Francisco · $500Kvia Johannes Fruehauf · board
RA CapitalreportedBostonvia Peter Kolchinsky · board

Reported raises · per SEC filings

Form D private placements
▶$57.3MraisedMar 2026 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Linda TusseyExecutive Officer
  • Kathryn KousdaExecutive Officer, Director
  • Livio ValentiExecutive Officer
  • Ann DeWittDirector
  • Fenel EloiDirector
  • Peter KolchinskyDirector
  • Rachel ShaExecutive Officer, Director
Offering amount
$83.5M
Amount sold
$57.3M
First sale
Mar 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.9MraisedSep 2025 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthew DirckxExecutive Officer
  • Jonathan KlugeExecutive Officer
  • Ann DeWittDirector
  • Fenel EloiDirector
  • Rachel ShaExecutive Officer, Director
  • Weiner TilsnerExecutive Officer
  • Peter KolchinskyDirector
  • Kathryn KosudaExecutive Officer, Director
  • Lynda TusseyExecutive Officer
  • John SpiridigliozziExecutive Officer
  • Livio ValentiExecutive Officer
Offering amount
$10M
Amount sold
$7.9M
First sale
Aug 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.4MraisedFeb 2025 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ann DeWittDirector
  • Matthew DirckxExecutive Officer
  • Lynda TusseyExecutive Officer
  • John SpiridigliozziExecutive Officer
  • Weiner TilsnerExecutive Officer
  • Livio ValentiExecutive Officer
  • Peter KolchinskyDirector
  • Jonathan KlugeExecutive Officer
  • Kathryn KosudaExecutive Officer, Director
  • Rachel ShaExecutive Officer, Director
  • Fenel EloiDirector
Offering amount
$10M
Amount sold
$8.4M
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.8MraisedMay 2024 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lynda TusseyExecutive Officer
  • Mario BarroDirector
  • Kathryn KosudaExecutive Officer, Director
  • Matthew DirckxExecutive Officer
  • Ann DeWittDirector
  • Weiner TilsnerExecutive Officer
  • John SpiridigliozziExecutive Officer
  • Rachel ShaExecutive Officer
  • Fenel EloiDirector
  • Jonathan KlugeExecutive Officer
  • Livio ValentiExecutive Officer
Offering amount
$12M
Amount sold
$10.8M
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.1MraisedJul 2023 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mario BarroDirector
  • Kathryn KosudaExecutive Officer, Director
  • Livio ValentiExecutive Officer
  • Jonathan KlugeExecutive Officer
  • Fenel EloiDirector
  • Ann DeWittDirector
  • Michael SchraderExecutive Officer, Director
  • Lynda TusseyExecutive Officer
Offering amount
$12.1M
Amount sold
$9.1M
First sale
Jul 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$35MraisedDec 2022 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kathryn KosudaExecutive Officer, Director
  • Ann DeWittDirector
  • Lynda TusseyExecutive Officer
  • Jonathan KlugeExecutive Officer
  • Michael SchraderExecutive Officer, Director
  • Mario BarroDirector
  • Fenel M. EloiDirector
  • Livio ValentiExecutive Officer
Offering amount
$35M
Amount sold
$35M
First sale
Apr 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedOct 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael SchraderExecutive Officer, Director
  • Mario BarroDirector
  • Ann DeWittDirector
  • Livio ValentiExecutive Officer
  • Jonathan KlugeExecutive Officer
  • Kathryn KosudaExecutive Officer, Director
  • Lynda TusseyExecutive Officer
  • Fenel M. EloiDirector
Offering amount
$2M
Amount sold
$2M
First sale
Sep 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedMar 2021 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Livio ValentiExecutive Officer
  • Jonathan KlugeExecutive Officer
  • Ted HibbenExecutive Officer
  • Ann DeWittDirector
  • Lynda TusseyExecutive Officer
  • Michael SchraderExecutive Officer, Director
  • Johannes FruehaufDirector
  • Kathryn KosudaExecutive Officer, Director
  • Purnanand SarmaDirector
Offering amount
$2M
Amount sold
$2M
First sale
Mar 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.